> Details

Teyssonneau, Diego; Thiery-Vuillemin, Antoine; Dariane, Charles; Barret, Eric; Beauval, Jean-Baptiste; Brureau, Laurent; Créhange, Gilles; Fiard, Gaëlle; Fromont, Gaëlle; Gauthé, Mathieu; Ruffion, Alain; Renard-Penna, Raphaële; Mathieu, Romain; Sargos, Paul; Rouprêt, Morgan; Ploussard, Guillaume; Roubaud, Guilhem

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
  • Contributor: Teyssonneau, Diego; Thiery-Vuillemin, Antoine; Dariane, Charles; Barret, Eric; Beauval, Jean-Baptiste; Brureau, Laurent; Créhange, Gilles; Fiard, Gaëlle; Fromont, Gaëlle; Gauthé, Mathieu; Ruffion, Alain; Renard-Penna, Raphaële; Mathieu, Romain; Sargos, Paul; Rouprêt, Morgan; Ploussard, Guillaume; Roubaud, Guilhem
  • imprint: MDPI AG, 2022
  • Published in: Journal of Clinical Medicine
  • Language: English
  • DOI: 10.3390/jcm11061734
  • ISSN: 2077-0383
  • Keywords: General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p>Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.</jats:p>
  • Access State: Open Access